Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering AG dermatology business “Intendis”

Executive Summary

Schering AG names separate dermatology business group Intendis. Company will formally begin operations Jan. 1. U.S. headquarters in Montville, N.J. will house about 70 out of approximately 600 global Intendis employees. Managing Director Wolfgang Kehr will lead global headquarters in Berlin. U.S. management will include North & Latin America Marketing & Sales head Bernhard Schefter. Schering announced in June it was spinning off "non-core" businesses to focus on oncology (1"The Pink Sheet" June 21, 2004, p. 38)....

You may also be interested in...



Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”

Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel